Drug Kras Mutated Recurrent Low-Grade Serous Ovarian Cancer (Lgsoc)

Avmapki Fakzynja Co-Pack

Payments companies reported to CMS as associated with Avmapki Fakzynja Co-Pack. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$32Kassociated payments (2023-2025)
213clinicians with associated payments
1company reporting

By year

2025 $32K

Payments reported as associated with Avmapki Fakzynja Co-Pack, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Anatomic Pathology & Clinical Pathology $17K
Anatomic Pathology $6,175
Gynecologic Oncology $1,611
Family $1,575
Nurse Practitioner $839
Hematology & Oncology $838

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Avmapki Fakzynja Co-Pack

These are the largest totals companies reported as associated with Avmapki Fakzynja Co-Pack. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Ie-Ming Shih Baltimore, MD Anatomic Pathology & Clinical Pathology $3,575.00
Pei Hui New Haven, CT Anatomic Pathology $3,575.00
Anna Yemelyanova New York, NY Anatomic Pathology & Clinical Pathology $3,575.00
Ricardo Lastra Chicago, IL Anatomic Pathology & Clinical Pathology $3,575.00
Kyle Devins Boston, MA Anatomic Pathology & Clinical Pathology $3,300.00
Teri Longacre Stanford, CA Anatomic Pathology & Clinical Pathology $3,038.75
Michael Chui Baltimore, MD Anatomic Pathology $2,600.00
Jasmin Popillion Baytown, TX Family $269.72
Mazdak Momeni Loma Linda, CA Gynecologic Oncology $153.12
Linda Hong Loma Linda, CA Gynecologic Oncology $153.12

Prescribed Avmapki Fakzynja Co-Pack?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.